A2i Therapeutics
Latest round
- Seed
Last raised
- Dec 2020
Total raised
- Undisclosed
Investors
- 4
About A2i Therapeutics
A2i Therapeutics was formed as a joint venture between Atomwise and FutuRx. The company operates as a developer of novel small molecule immuno-oncology agents.
Who invested in A2i Therapeutics
4 investors across 1 round
See all investors in A2i Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Dec 18, 2020
Amount
Undisclosed
Investors
Questions about A2i Therapeutics
Who invested in A2i Therapeutics?
A2i Therapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has A2i Therapeutics raised?
A2i Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did A2i Therapeutics last raise money?
A2i Therapeutics's most recent round on record is a Seed, in Dec 2020.
What does A2i Therapeutics do?
A2i Therapeutics was formed as a joint venture between Atomwise and FutuRx.
Where is A2i Therapeutics headquartered?
A2i Therapeutics is headquartered in Israel.
Which VCs invest in companies like A2i Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at A2i Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like A2i Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.